pioglitazone / Generic mfg.  >>  Phase 1
Welcome,         Profile    Billing    Logout  

12 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pioglitazone / Generic mfg.
NCT01586078: Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Patients With Brain Tumors

Recruiting
1
100
US
pioglitazone hydrochloride, Actos, pioglitazone, laboratory biomarker analysis, external beam radiation therapy, EBRT, 3-dimensional conformal radiation therapy, 3D-CRT, conformal radiation therapy, intensity-modulated radiation therapy, IMRT, management of therapy complications, complications of therapy, management of
Comprehensive Cancer Center of Wake Forest University, National Cancer Institute (NCI)
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Meningioma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Choroid Plexus Tumor, Adult Craniopharyngioma, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Medulloblastoma, Adult Meningeal Hemangiopericytoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Papillary Meningioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Pineoblastoma, Adult Pineocytoma, Adult Subependymal Giant Cell Astrocytoma, Adult Subependymoma, Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Meningeal Melanocytoma, Nonmalignant Neoplasm, Recurrent Adult Brain Tumor, Tumors Metastatic to Brain
09/14
 
NCT02592317: A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer

Recruiting
1
20
Europe, RoW
JNJ 56021927, Drug Cocktail, Pioglitazone, Rosuvastatin
Aragon Pharmaceuticals, Inc.
Prostatic Neoplasms, Castration-Resistant
11/16
12/24
ChiCTR2000032539: The human bioequivalence test of Pioglitazone Hydrochloride tablets

Completed
1
64
 
After fasting overnight for at least 10 hours, oral one tablet of the test preparation or reference preparation was taken with 200mL 20% glucose solution on an empty stomach in the morning of the test day, once every cycle, then subjects were gargled with 40mL water. Cross-administration after ten days. ;After fasting overnight for at least 10 hours, eat a high-fat and high-calorie standard meal 30 minutes before taking 1 test preparation or the reference preparation with 200mL 20% glucose solution in the morning of the test day, once every cycle, then subjects were gargled with 40mL water. Cross-administra ;After fasting overnight for at least 10 hours, one tablet of the test preparation or reference preparation was taken with 200mL 20% glucose solution on an empty stomach in the morning of the test day, once every cycle, then subjects were gargled with 40mL water. Cross-administration after ten days ;After fasting overnight for at least 10 hours, eat a high-fat and high-calorie standard meal 30 minutes before taking 1 test preparation or the reference preparation with 200mL 20% glucose solution in the morning of the test day, once every cycle, then subjects were gargled with 40mL water. Cross-administra
NanJing First Hospital; Jiangsu Deyuan Pharmaceutical Co., Ltd., fully self-financing
Type 2 diabetes
 
 
ChiCTR2000032538: Study for the bioequivalence of Pioglitazone Hydrochloride and Metformin hydrochloride (15mg/500mg) tablets

Completed
1
59
 
After fasting overnight for at least 10 hours, oral one tablet of the test preparation or reference preparation with 200mL 20% glucose solution on an empty stomach in the morning of the test day, once every cycle, then subjects were gargled with 40mL water. Cross-administration after ten days ;After fasting overnight for at least 10 hours, eat a high-fat and high-calorie standard meal 30 minutes before taking 1 test preparation or the reference preparation with 200mL 20% glucose solution in the morning of the test day, once every cycle, then subjects were gargled with 40mL water. Cross-administra
Nanjing First Hospital; Jiangsu Deyuan Pharmaceutical Co., Ltd., fully self-financing
Type 2 diabetes
 
 
NCT02535832: Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA)

Completed
1
16
US
Pioglitazone, Actos, Placebo
Ohio State University
Rheumatoid Arthritis, Insulin Resistance
10/22
10/22
NCT04658849: Insulin Resistance Following ADT for Prostate CA

Withdrawn
1
44
US
Pioglitazone 30 Mg Oral Tablet, Actos, Pioglitazone placebo tablet, Placebo
St. Louis University
Insulin Resistance, Prostate Cancer
03/23
03/23
NCT03720366: A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients

Completed
1
40
RoW
enasidenib, CC-90007, AG-221, Arm 1 probes, Arm 2 Probes, Arm 3 probes
Celgene
Leukemia, Myeloid, Acute
09/23
12/23
NCT05760677: Study on the Efficacy and Safety of Chiglitazar Sodium in PCOS With T2DM

Enrolling by invitation
1
142
RoW
pioglitazone group: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone, the Chiglitazar group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar
Affiliated Hospital of Nantong University
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, T2D
09/23
09/24
PIOGAS, NCT04300127: Pioglitazone for Idiopathic Gastroparesis

Active, not recruiting
1
10
US
Pioglitazone 30 mg
Johns Hopkins University
Gastroparesis
09/25
10/25
NCT03866408: Insulin Regulation of Lipolysis and Lipolysis Proteins

Recruiting
1
64
US
Immediate weight loss, Pioglitazone, Deferred weight loss, Placebo
Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Obesity
12/24
12/24
NCT05960656: SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis

Recruiting
1
169
US
Empagliflozin 25 MG, Jardiance, Placebo, Placebo for empagliflozin, Pioglitazone 30mg, Actos, Pioglitazone 30mg + Empagliflozin (25 mg), Actos/Jardiance
The University of Texas Health Science Center at San Antonio, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 2 Diabetes, Type 1 Diabetes
06/27
06/27
NCT05753657: A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.

Recruiting
1
30
RoW
Pioglitazone
Rambam Health Care Campus
Metastatic Breast Cancer, Hyperinsulinism, Hyperglycemia Drug Induced
12/26
12/27

Download Options